

CORRECTION

INFORMATION ONLY

Launch of Hizentra™ 20%, Subcutaneous Immune Globulin (Human)
Customer Letter # 2012-02

2012-01-30

Dear Customer:

This Customer Letter first issued by Canadian Blood Services (CBS) on January 17, 2012 provided the following comparison Table.


Please note that there was a typo for the first measurement of IgA content for Hizentra™

The IgA content for Hizentra™ should read “No more than 50 mg/L (average of 8 mg/L)” not 50 mg/mL.

Feature	Vivaglobin®	Hizentra™
Concentration	16%	20%
Storage	2-8°C	2-25°C
IgA content	Not provided in Product Monograph	No more than 50 mg/L (average of 8 mg/L)
Infusion rate	In clinical studies, a volume of 15 mL per injection site at a rate of 20 mL per hour per site was not exceeded. Doses over 15 mL were divided and infused simultaneously into several sites.	For the first infusion of Hizentra, the maximum recommended flow rate is 15 mL per hour per site. For subsequent infusions, the flow rate may be increased to a maximum of 34 mL per hour per site as tolerated. The maximum flow rate observed in the clinical study was 70 mL per hour for all sites combined at any time.
Indication	Primary immune deficiency (PID)	Primary immune deficiency (PID) and Secondary immune deficiency (SID)

We sincerely regret any confusion this error may have caused. This Customer Letter can also be viewed at www.blood.ca in the “Hospitals” section. If you have questions about this Customer Letter, please contact your local Canadian Blood Services Hospital Liaison Specialist.

Sincerely,



Dana Devine, Ph.D.
Vice President, Medical, Scientific & Research Affairs